Clinical Trial Update: Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer [Phase 1]

View source ↗

Summary

Olema Pharmaceuticals reports a Phase 1b trial evaluating OP-1250 (palazestrant) in combination with ribociclib, alpelisib, everolimus, or atirmociclib for ER-p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Alpelisib (alpelisib)
• Atirmociclib (atirmociclib)
• Everolimus (everolimus)
• OP-1250 (Palazestrant) (palazestrant)
• Ribociclib (ribociclib)

Snippet

Sponsor: Olema Pharmaceuticals, Inc. | Conditions: Metastatic Breast Cancer, ER-positive Breast Cancer | Phase 1 | Status: RECRUITING